XSTO
ACE
Market cap51mUSD
Jun 19, Last price
4.22SEK
1D
-0.24%
1Q
37.46%
IPO
-85.60%
Name
Ascelia Pharma AB
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.89%
Rev. gr., 5y
%
Revenues
0k
Net income
-80m
L-26.77%
CFO
-63m
L-50.44%
Earnings
Aug 13, 2025
Profile
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 69,462 | 112,527 | 117,782 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (69,462) | (112,527) | (117,782) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 94 | (319) | (1,933) | ||||||
Tax Rate | |||||||||
NOPAT | (69,556) | (112,208) | (115,849) | ||||||
Net income | (80,029) -26.77% | (109,288) -16.72% | (131,222) 4.22% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 105,324 | (89) | (84) | ||||||
BB yield | -66.79% | 0.08% | 0.02% | ||||||
| Debt | |||||||||
Debt current | 25,397 | 884 | 291 | ||||||
Long-term debt | 172 | 1,236 | 677 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | (1,000) | ||||||||
Net debt | (49,687) | (19,735) | (148,587) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (62,844) | (126,792) | (125,263) | ||||||
CAPEX | (65) | ||||||||
Cash from investing activities | 46 | (65) | |||||||
Cash from financing activities | 115,187 | (936) | (1) | ||||||
FCF | (68,619) | (112,643) | (114,656) | ||||||
| Balance | |||||||||
Cash | 75,256 | 21,855 | 149,555 | ||||||
Long term investments | |||||||||
Excess cash | 75,256 | 21,855 | 149,555 | ||||||
Stockholders' equity | (643,780) | (604,420) | (497,889) | ||||||
Invested Capital | 748,121 | 679,808 | 679,231 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 54,001 | 33,720 | 33,668 | ||||||
Price | 2.92 -13.35% | 3.37 -77.44% | 14.94 -49.95% | ||||||
Market cap | 157,683 38.76% | 113,636 -77.41% | 503,004 -48.87% | ||||||
EV | 107,996 | 93,901 | 354,417 | ||||||
EBITDA | (69,462) | (111,478) | (116,736) | ||||||
EV/EBITDA | |||||||||
Interest | 14 | 48 | |||||||
Interest/NOPBT | |||||||||